ASCO 2026: AI Challenges a Breast Cancer Standard - Top-Institutions - MDSpire

ASCO 2026: AI Challenges a Breast Cancer Standard

New data suggest AI-based analysis of pathology slides may provide additional prognostic information, particularly for patients in the intermediate-risk category

  • By

  • Jessica Allerton

  • June 4, 2026

  • 3 min

Share

Top Institutions in Pathology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Breast Oncology

  • #2

    Harvard Medical School
    Harvard Medical School

    Boston, MA

    Key Differentiators

    • Medicine

  • #3

    University of Alabama at Birmingham
    University of Alabama at Birmingham

    Birmingham, AL

    Key Differentiators

    • Radiation Oncology

  • #4

    University of California, San Francisco
    University of California, San Francisco

    San Francisco, CA

    Key Differentiators

    • Medicine

  • #5

    University of California San Diego Moores Cancer Center
    University of California San Diego Moores Cancer Center

    La Jolla, CA

    Key Differentiators

    • Medical Oncology

Original Source(s)

ASCO 2026: AI Challenges a Breast Cancer Standard

  • by Jessica Allerton

  • June 4, 2026

Related Content

New Clues in Hodgkin Lymphoma Biology

Transcriptome analysis highlights diagnostic targets and immune evasion pathways

  • May 14, 2026

  • 2 min
Case series analysis of immunophenotypic evolution during recurrence of low-grade endometrial stromal sarcoma: implications for molecular stability and clinical management

Why We Made a Mobile Digital Pathology Lab

Todd R. Minnigh and his team created ScanVan to address a problem with rare cancer diagnosis that had a particularly personal significance